These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 3140691)
21. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine. Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854 [TBL] [Abstract][Full Text] [Related]
22. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Fonne-Pfister R; Meyer UA Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741 [TBL] [Abstract][Full Text] [Related]
23. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population. Du YL; Lou YQ Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020 [TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Boobis AR; Murray S; Hampden CE; Davies DS Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916 [TBL] [Abstract][Full Text] [Related]
26. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver. von Bahr C; Birgersson C; Blanck A; Göransson M; Mellström B; Nilsell K Life Sci; 1983 Aug; 33(7):631-6. PubMed ID: 6410141 [TBL] [Abstract][Full Text] [Related]
27. Metabolism of alfentanil by isolated hepatocytes of rat and dog. Lavrijsen K; Van Houdt J; Meuldermans W; Knaeps F; Hendrickx J; Lauwers W; Hurkmans R; Heykants J Xenobiotica; 1988 Feb; 18(2):183-97. PubMed ID: 3131971 [TBL] [Abstract][Full Text] [Related]
28. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974 [TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468 [TBL] [Abstract][Full Text] [Related]
30. Irreversible binding and metabolism of propranolol by human liver microsomes--relationship to polymorphic oxidation. Shaw L; Lennard MS; Tucker GT; Bax ND; Woods HF Biochem Pharmacol; 1987 Jul; 36(14):2283-8. PubMed ID: 3111480 [TBL] [Abstract][Full Text] [Related]
31. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results. Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535 [TBL] [Abstract][Full Text] [Related]
32. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348 [TBL] [Abstract][Full Text] [Related]
33. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236 [TBL] [Abstract][Full Text] [Related]
34. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304 [TBL] [Abstract][Full Text] [Related]
35. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Otton SV; Inaba T; Mahon WA; Kalow W Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751 [TBL] [Abstract][Full Text] [Related]
36. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes. Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620 [TBL] [Abstract][Full Text] [Related]
37. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Labroo RB; Thummel KE; Kunze KL; Podoll T; Trager WF; Kharasch ED Drug Metab Dispos; 1995 Apr; 23(4):490-6. PubMed ID: 7600917 [TBL] [Abstract][Full Text] [Related]
38. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534 [TBL] [Abstract][Full Text] [Related]
39. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling. Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638 [TBL] [Abstract][Full Text] [Related]
40. Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human hepatic microsomes. Marre F; Fabre G; Lacarelle B; Bourrie M; Catalin J; Berger Y; Rahmani R; Cano JP Drug Metab Dispos; 1992; 20(2):316-21. PubMed ID: 1352227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]